Recovery of cardiac norepinephrine concentration and tyrosine hydroxylase activity by the central α2-adrenoceptor agonist guanabenz in rats with aortic constriction

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 3, 1999, Pages 409-413

  Takechi, Shigeru ^a   Nomura, Akikazu ^a   Shimono, Hisashi ^a   Katoh, Kunihiko ^a   Kakinoki, Shigeo ^a   Jin, En Ze ^a   Akutsu, Mitsuyuki ^a   Kitabatake, Akira ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Dihydroxyphenylglycol; Regression of cardiac hypertrophy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; GUANABENZ; NORADRENALIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; HEART FAILURE; HORMONE DETERMINATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENAL GLANDS; ADRENERGIC ALPHA-AGONISTS; ANIMALS; AORTA, THORACIC; BODY WEIGHT; CONSTRICTION; GUANABENZ; HEART; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; LIVER; MALE; METHOXYHYDROXYPHENYLGLYCOL; MYOCARDIUM; NOREPINEPHRINE; ORGAN SIZE; RATS; RATS, WISTAR; SPLEEN; TYROSINE 3-MONOOXYGENASE; VAS DEFERENS;

EID: 0033041022     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199903000-00010     Document Type: Article

References (30)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
2. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captoril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
3. Cohn JN, Levine B, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 1984;311:819-23.
4. Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequence of high sympathetic nerve activity in failing human heart. J Am Coll Cardiol 1995;26:1257-63.
5. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;93:1667-76.
6. Madsen BK, Keller N, Christiansen E, Christennsen NJ. Prognostic value of plasma catecholamines, plasma renin activity, and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: comparison with clinical evaluation, ejection fraction, and exercise capacity. J Cardiac Fail 1995;1:207-16.
7. Spann JF, Chidsey CA, Pool PE, Braunwald E. Mechanism of norepinephrine depletion in experimental heart failure by aortic constriction in the guinea pig. Circ Res 1965;17:312-21.
8. Covell JW, Chidsey CA, Braunwald E. Reduction of the cardiac response to postganglionic sympathetic nerve stimulation in experimental heart failure. Circ Res 1966;19:51-6.
9. Lambert GW, Kaye DM, Lefkovits J, et al. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients. Circulation 1995;92:1813-8.
10. Eichhorn EJ, Hjalmarson A. β-B locker treatment for chronic heart failure. Circulation 1994;90:2153-6.
11. Weber MA, Drayer JIM. Centrally acting antihypertensive agents: a brief overview. J Cardiovasc Pharmacol 1984;6:S803-7.
12. Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkoffer RL. Short-term effects of intravenous clonidine in congestive heart failure. Clin Pharmacol Ther 1981;30:724-8.
13. Olivari MT, Levine B, Cohn JN, et al. Acute hemodynamic and hormonal effects of central versus peripheral sympathetic inhibition in patients with congestive heart failure. J Cardiovasc Pharmacol 1986;8:973-7.
14. Kirlin PC, Das S, Grekin R, et al. Sympathetic inhibition with methyldopa in heart failure. J Cardiovasc Pharmacol 1986;8:1092-100.
15. Giles TD, Thomas MG, Quiroz AC, Rice JC, Plauche W, Sander GE. Acute and short-term effects of clonidine in heart failure. Angiology 1987;38:537-48.
16. Blank CL, Pike R. A novel, inexpensive, and sensitive method for analysis of tyrosine hydroxylase activity in tissue samples. Life Sci 1976;18:859-66.
17. Nomura A, Yasuda H, Katoh K, et al. Continuous blood pressure recording in patients with pheochromocytoma of the urinary bladder. Am J Hypertens 1991;4:189-91.
18. Pool PE, Covell JW, Levitt M, Gibb J, Braunwald E. Reduction of cardiac tyrosine hydroxylase activity in experimental congestive heart failure. Circ Res 1967;20:349-53.
19. Bohm M, Rosee KL, Schwinger RHG, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the human heart. J Am Coll Cardiol 1995;25:146-53.
20. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997;95: 169-75.
21. Chidsey CA, Braunwald E, Morrow A, Mason DT. Myocardial norepinephrine concentration in man. N Engl J Med 1963;269: 653-8.
22. Nagasaka Y, Kasai H, Matsunaga T, et al. Acute and subacute toxicity studies of guanabenz. Jpn Pharmacol Ther 1982;10:4571-97.
23. Hanbauer I, Kopin IJ, Guidotti A, Costa E. Induction of tyrosine hydroxylase elicited by beta adrenergic receptor agonists in normal and decentralized sympathetic ganglia: role of cyclic 3′,5′-adenosine monophosphate. J Pharmacol Exp Ther 1975;193: 95-104.
24. Thoenen H, Mueller RA, Axelrod J. Increased tyrosine hydroxylase activity after drug-induced alteration of sympathetic transmission. Nature 1969;221:1254.
25. Howes LG, Hodsman GP, Maccarrone C, Kohzuki M, Johnston CI. Cardiac 3,4-dihydroxyphenylethylene glycol (DHPG) and catecholamine levels in a rat model of left ventricular failure. J Cardiovasc Pharmacol 1989;13:348-52.
26. Eisenhofer G, Esler MD, Meredith IT, et al. Sympathetic nervous function in human heart as assessed by spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 1992;85:1775-85.
27. Partanen S, Penttila O, Kyosola K, Merikallio E, Siltanen P. Histochemically demonstrable monoamine oxidase activity in the adult human heart in various cardiac disease. Virchows Arch A Path Anat Histol 1976;370;291-6.
28. 2-adrenergic agents in anaesthesia Acta Anaesthesiol Scand 1993;37:433-48.
29. 2-adrenoceptor agonist. Cardiovasc Drugs Ther 1993;7:929-34.
30. Lepran I, Papp JG. Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 1994;24(suppl 1):S9-15.